I agree with both your thoughts and CSK..
If you consider this (effectively capital payment fully franked) your net cost at risk for the ongoing shares is 78 cents for the pathology bus
So the real risk issue is the pathology business not turning round.
i think it will turn round and i would not not expect the major shareholders will bail if that’s their view. The CSK report is well thought out
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
84.0¢ |
Change
0.040(5.00%) |
Mkt cap ! $609.9M | |||
| Open | High | Low | Value | Volume |
| 81.0¢ | 85.0¢ | 80.8¢ | $7.570M | 9.024M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12500 | 83.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 85.0¢ | 179631 | 10 |
View Market Depth
| Last trade - 16.11pm 07/08/2025 (20 minute delay) ? |
| HLS (ASX) Chart |